Serum Albumin

Serum albumin is a protein made by the liver and is present in the blood plasma. It is an important biomarker routinely used in clinical practice by hematology and oncology researchers. Serum albumin levels are commonly used to assess patients' nutritional status, liver function, and the severity of some conditions such as cancer, kidney disease, and heart failure. In hematology research, serum albumin levels are correlated with overall survival in patients with hematological malignancies, such as leukemia, lymphoma, and multiple myeloma. Low levels of serum albumin in these patients are associated with an increased risk of complications, including infections and blood clotting disorders. In oncology research, serum albumin levels can indicate the presence of cachexia, a condition characterized by the extreme wasting of muscle and adipose tissue. Cachexia is a common complication of cancer and is associated with poor prognosis and decreased response to treatment. Serum albumin levels can also be used to assess the effectiveness of cancer treatment, especially chemotherapy. In cases where albumin levels decrease after treatment initiation, it can indicate a poor response to the therapy. Additionally, hematology and oncology research has shown that low serum albumin levels increase the risk of chemotherapy-induced toxicity and can lead to treatment interruption or discontinuation. Overall, serum albumin is a useful biomarker in hematology and oncology research. It provides clinicians and researchers with important information about patients' nutritional status, liver function, and the severity of some conditions, as well as being an indicator of treatment response and toxicity.